Canaccord analyst Whitney Ijem lowered the firm’s price target on Vertex Pharmaceuticals to $378 from $379 and keeps a Sell rating on the shares. The firm continues to think current trading levels are pricing in better-than-our-best-case for VX-548 but are increasing the probability of success to 90% versus 40% previously.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX: